Previous Article | Next Article ![]()
Journal of Clinical Microbiology, Oct 1997, 2531-2536, Vol 35, No. 10
S Bascomb, SL Abbott, JD Bobolis, DA Bruckner, SJ Connell, SK Cullen, M Daugherty, D Glenn, JM Janda, SJ Lentsch, D Lindquist, PB Mayhew, DM Nothaft, JR Skinner, GB Williams, J Wong and BL Zimmer
The accuracy and performance of the revised MicroScan Rapid Gram- Negative
Identification Type 3 Panel (Dade MicroScan Inc., West Sacramento, Calif.)
were examined in a multicenter evaluation. The revised panel database
includes data for 119 taxa covering a total of 150 species, with data for
12 new species added. Testing was performed in three phases: the efficacy,
challenge, and reproducibility testing phases. A total of 405 fresh and
stock gram-negative isolates comprising 54 species were tested in the
efficacy phase; 96.8% of these species were identified correctly in
comparison to the identification obtained either with the API 20E system
(bioMerieux Vitek, Hazelwood, Mo.) or by the conventional tube method. The
number of correctly identified isolates in the challenge phase, including
new species added to the database, was 221 of 247, or 89.5%, in comparison
to the number correctly identified by the conventional tube method. A total
of 465 isolates were examined for intra- and interlaboratory identification
reproducibility and gave an agreement of 464 of 465, or 99.8%. The overall
reproducibility of each individual identification test or substrate was
14,373 of 14,384, or 99.9%. The new Rapid Gram-Negative Identification Type
3 Panel gave accurate and highly reproducible results in this
multiple-laboratory evaluation.
Copyright © 1997 by the American Society for Microbiology. All rights reserved.
Multicenter evaluation of the MicroScan Rapid Gram-Negative Identification Type 3 Panel
Dade MicroScan Inc., West Sacramento, California 95691, USA.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|